|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0011777,
umls-concept:C0013089,
umls-concept:C0013216,
umls-concept:C0025815,
umls-concept:C0026764,
umls-concept:C0039736,
umls-concept:C0040736,
umls-concept:C0042679,
umls-concept:C0205195,
umls-concept:C0205263,
umls-concept:C0332152,
umls-concept:C0936012,
umls-concept:C1523987,
umls-concept:C1589416,
umls-concept:C1704419
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-11-19
|
|
pubmed:abstractText |
A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients. The response rate after three cycles of treatment was statistically higher with CTD (n = 27) compared to CVAMP (n = 27) (89% vs. 56%, P = 0.016). Toxicity studies showed more neutropenia (grade 3/4) (4% vs. 60%, P = 0.0002) with CVAMP and more thrombotic episodes with CTD (11% vs. 4%). CTD may emerge as the superior induction regimen prior to PBSCT, in terms of high efficacy and better tolerability.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
pubmed-author:AlvaresCaroline LCL,
pubmed-author:DaviesFaith EFE,
pubmed-author:DinesSharonS,
pubmed-author:EthellMark EME,
pubmed-author:HortonCliveC,
pubmed-author:JennerMatthew WMW,
pubmed-author:KrishnanBijuB,
pubmed-author:McCormackRitaR,
pubmed-author:MorganGareth JGJ,
pubmed-author:PotterMichael NMN,
pubmed-author:SasoRadovanR,
pubmed-author:TreleavenJennifer GJG,
pubmed-author:WuPingP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2335-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17107906-Adult,
pubmed-meshheading:17107906-Aged,
pubmed-meshheading:17107906-Antineoplastic Agents,
pubmed-meshheading:17107906-Case-Control Studies,
pubmed-meshheading:17107906-Cyclophosphamide,
pubmed-meshheading:17107906-Dexamethasone,
pubmed-meshheading:17107906-Doxorubicin,
pubmed-meshheading:17107906-Drug Therapy, Combination,
pubmed-meshheading:17107906-Female,
pubmed-meshheading:17107906-Humans,
pubmed-meshheading:17107906-Male,
pubmed-meshheading:17107906-Methylprednisolone,
pubmed-meshheading:17107906-Middle Aged,
pubmed-meshheading:17107906-Multiple Myeloma,
pubmed-meshheading:17107906-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:17107906-Thalidomide,
pubmed-meshheading:17107906-Transplantation, Autologous,
pubmed-meshheading:17107906-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
|
|
pubmed:affiliation |
Haemato-Oncology Unit, Royal Marsden Hosptial, Sutton, Surrey, UK.
|
|
pubmed:publicationType |
Journal Article
|
